Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Triple Negative Breast Cancer|Stage IV Breast Cancer|Metastatic Breast Cancer
Interventions: DRUG: Abraxane alone|DRUG: Abraxane + Tigatuzumab
Sponsor: University of Alabama at Birmingham
Collaborators: Susan G. Komen Breast Cancer Foundation|Daiichi Sankyo UK Ltd.|Triple Negative Breast Cancer Foundation